Abstract
Protein tyrosine phosphatases (PTPs) are important in the regulation of diverse cellular functions including proliferation, migration and invasion; aberration of these cellular events is crucial for the development and progression of cancer. PTPs family comprises of two groups, classic PTPs and dual specificity phosphatases. The classic PTPs include both non-transmembrane PTPs and transmembrane receptor-like PTPs (RPTPs). RPTPs are composed of extracellular regions, transmembrane domains and intracellular phosphatase domains. The extracellular regions of RPTPs are similar to cell adhesion molecules and can interact homophilically and heterophilically. There are eight subgroups in the RPTPs separated according to the differences in their extracellular regions. PTPRK and PTPRM belong to the R2B subfamily of RPTPs and both perform homophilic interactions and regulate cell-cell aggregation and adhesion. Furthermore, both PTPRK and PTPRM can interact with the catenin/cadherin complex to regulate cell proliferation and migration. The current review discusses the present knowledge on RPTPs and their potential implication in the development and progression of cancer.
Keywords: Cancer, motility, proliferation, protein tyrosine phosphatases, PTPRK, PTPRM and signal transductions.
Current Signal Transduction Therapy
Title:Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Volume: 8 Issue: 2
Author(s): Ping-Hui Sun, Lin Ye, Malcolm D D. Mason and Wen G. Jiang
Affiliation:
Keywords: Cancer, motility, proliferation, protein tyrosine phosphatases, PTPRK, PTPRM and signal transductions.
Abstract: Protein tyrosine phosphatases (PTPs) are important in the regulation of diverse cellular functions including proliferation, migration and invasion; aberration of these cellular events is crucial for the development and progression of cancer. PTPs family comprises of two groups, classic PTPs and dual specificity phosphatases. The classic PTPs include both non-transmembrane PTPs and transmembrane receptor-like PTPs (RPTPs). RPTPs are composed of extracellular regions, transmembrane domains and intracellular phosphatase domains. The extracellular regions of RPTPs are similar to cell adhesion molecules and can interact homophilically and heterophilically. There are eight subgroups in the RPTPs separated according to the differences in their extracellular regions. PTPRK and PTPRM belong to the R2B subfamily of RPTPs and both perform homophilic interactions and regulate cell-cell aggregation and adhesion. Furthermore, both PTPRK and PTPRM can interact with the catenin/cadherin complex to regulate cell proliferation and migration. The current review discusses the present knowledge on RPTPs and their potential implication in the development and progression of cancer.
Export Options
About this article
Cite this article as:
Sun Ping-Hui, Ye Lin, Mason D. Malcolm D and Jiang G. Wen, Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ), Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660003
DOI https://dx.doi.org/10.2174/15743624113086660003 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selected Attributes of Polyphenols in Targeting Oxidative Stress in Cancer
Current Topics in Medicinal Chemistry The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Retraction Notice: The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
Current Drug Safety Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Medicinal Value and Potential Therapeutic Mechanisms of Gynostemma pentaphyllum (Thunb.) Makino and Its Derivatives: An Overview
Current Topics in Medicinal Chemistry Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy
Current Pharmacogenomics Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Hydrogen Sulfide-Based Anti-Inflammatory and Chemopreventive Therapies: An Experimental Approach
Current Pharmaceutical Design Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets